Adherium (ASX:ADR) Stock Falls: Key Reasons Explained

Sonal Goyal

05 November 2026 01:55 PM AEDT

Adherium (ASX:ADR) Stock Falls: Key Reasons Explained

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Shares traded at A$0.061 during the 5 November 2026 session, down 8.96%.
Remote patient monitoring Revenue was A$539,000 for the quarter, up 12.5% on the prior quarter.
John Perry has been appointed Interim Chief Executive Officer as the company moves into its value-based care growth phase.

Shares in Adherium Limited (ASX:ADR) traded at A$0.061 during the Trading session on 5 November 2026, down 8.96% in the early afternoon. The S&P/ASX 200 was up 1.87%, trading near 9,000 points. Adherium is a digital respiratory management company that develops the FDA-cleared Hailie Sensor and the Smartinhaler platform. Its latest update is a quarterly activities report and Appendix 4C dated 30 October 2026, covering the quarter ended 30 September 2026.

Quarterly report released 30 October 2026

Adherium reported remote patient monitoring subscription accrual revenue of A$539,000, up 12.5% on the prior quarter and the fifth consecutive quarter of record revenue in that category. Customer cash receipts were A$544,000, up 33% quarter on quarter, including a A$257,917 Cash Receipt from the AstraZeneca Arrival study.

The company added 1,033 device shipments and 900 device activations in the quarter, bringing cumulative totals to 6,392 shipments and 4,732 activations. It also appointed John Perry as Interim Chief Executive Officer, as announced on 29 July 2026, and partnered with Florida Lung, Asthma & Sleep Specialists after quarter end.

Sector context

At midday, the ASX Health Care sector was up 3.08%. Adherium shares moved lower in the session, against that gain. The Quarterly Report is dated 30 October and is not linked to the 5 November price move.

What to watch ahead

Investors will be following device shipment and activation trends, the conversion of shipments into billable revenue and the outcome of the Leadership transition to a permanent chief executive. The Florida Partnership and the expansion of the Hailie platform in the United States will also be followed.

Risks

Device shipments are a lead indicator of recurring revenue, but billable revenue is recognised only as patients are activated, so timing can vary. The leadership transition is interim, and the company operates in the US market where reimbursement and adoption can change. The shares are low-priced and can be volatile.

Final Word

Adherium's latest quarter shows growth in its Recurring Revenue and device base alongside a change in leadership. The share price fell during the session, and the company's next quarterly update will show how activations translate into revenue.

FAQs

Q: Why did Adherium shares fall on 5 November 2026?

A: Shares traded at A$0.061, down 8.96%, during the session. The quarterly report is dated 30 October 2026 and is not linked to the price move.

Q: What was Adherium's remote patient monitoring revenue?

A: Subscription accrual revenue was A$539,000 for the quarter, up 12.5% on the prior quarter.

Q: Who is leading Adherium on an interim basis?

A: John Perry has been appointed Interim Chief Executive Officer.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.